Pharmacokinetics and Safety of Micafungin in Infants Supported with Extracorporeal Membrane Oxygenation

Pediatric Infectious Disease Journal

Volumn 35, Issue 11, 2016, Pages 1204-1210

  Autmizguine, Julie ^a   Hornik, Christoph P ^b   Benjamin, Daniel K ^b   Brouwer, Kim L R ^c   Hupp, Susan R ^b   Cohen Wolkowiez, Michael ^b   Watt, Kevin M ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

antifungal; Candida prophylaxis; Candida therapy; extracorporeal membrane oxygenation; infants; micafungin; pharmacokinetics

Indexed keywords

CREATININE; FRESH FROZEN PLASMA; HEPARIN; MICAFUNGIN; SERUM ALBUMIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOFILTRATION; HUMAN; INFANT; INVASIVE CANDIDIASIS; MALE; NECROTIZING ENTEROCOLITIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; VOLUME OF DISTRIBUTION; ANTIBIOTIC PROPHYLAXIS; BLOOD; CANDIDIASIS; NEWBORN;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDIASIS; ECHINOCANDINS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIPOPEPTIDES; MALE; MICAFUNGIN; PROSPECTIVE STUDIES;

EID: 84975112369     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001268     Document Type: Article

References (40)

1. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010;76:534-540.
2. Bizzarro MJ, Conrad SA, Kaufman DA, et al; Extracorporeal Life Support Organization Task Force on Infections, Extracorporeal Membrane Oxygenation. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12:277-281.
3. Andes D, Nett J, Oschel P, et al. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72:6023-6031.
4. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J. 1989;8:99-104.
5. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
6. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother. 2000;44:614-618.
7. Kaneko Y, Ohno H, Fukazawa H, et al. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med Mycol. 2010;48:606-612.
8. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57-62.
9. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40:1139-1142.
10. Watt KM, Benjamin DK Jr., Cheifetz IM, et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J. 2012;31:1042-1047.
11. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33:1018-1024.
12. Watt K, Cohen-Wolkoweiz W, Williams D, et al. Antifungal extraction by the extracorporeal membrane oxygenation (ECMO) circuit ex vivo. Paper presented at: American Society for Clinical Pharmacology and Therapeutics Annual meeting; March 3-7, 2015; New Orleans, LA.
13. Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109-2116.
14. Shekar K, Roberts JA, Mcdonald CI, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19:164.
15. Astellas. Mycamine (micafungin) [package insert]. 2013. Available at: http://www.astellas.us/docs/mycamine.pdf. Accessed July 21, 2016.
16. European Medicines Agency. Assessment report for Mycamine. April 24, 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Public-assessment-report/human/000734/WC500031079. pdf. Accessed July 21, 2016.
17. Lat A, Thompson GR III, Rinaldi MG, et al. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob Agents Chemother. 2010;54:943-944.
18. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1992;12:28-32.
19. Hope WW, Kaibara A, Roy M, et al. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. Antimicrob Agents Chemother. 2015;59:905-913.
20. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989;33:817-819.
21. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
22. Kuse ER, Chetchotisakd P, da Cunha CA, et al; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet. 2007;369:1519-1527.
23. van Burik JA, Ratanatharathorn V, Stepan DE, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
24. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
25. Benjamin DK Jr., Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93-99.
26. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412-415.
27. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis. 2000;31:458-463.
28. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714-3719.
29. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998;18:1082-1086.
30. Cohen P, Collart L, Prober CG, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J. 1990;9:562-566.
31. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm. 1990;9:711-715.
32. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991;37:16-18.
33. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901-D906.
34. Yanni SB, Augustijns PF, Benjamin DK Jr., et al. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos. 2010;38:1848-1856.
35. Gupta P, Carlson J, Wells D, et al. Relationship between renal function and extracorporeal membrane oxygenation use: a single-center experience. Artif Organs. 2015;39:369-374.
36. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145-1152.
37. Undre N, Pretorius B, Stevenson P. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction. Eur J Drug Metab Pharmacokinet. 2015;40:285-293.
38. Abrams D, Bacchetta M, Brodie D. Recirculation in venovenous extracorporeal membrane oxygenation. ASAIO J. 2015;61:115-121.
39. Nam MJ, Lim CH, Kim HJ, et al. A meta-analysis of renal function after adult cardiac surgery with pulsatile perfusion. Artif Organs. 2015;39:788-794.
40. Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull. 2006;29:1706-1711.